Analysts expect TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) to report $-0.19 EPS on August, 14.They anticipate $0.14 EPS change or 42.42 % from last ...
Feeds
32378 items (32378 unread) in 74 feeds
Acinar Cell Carcinoma
(227 unread)
Acinic Cell Carcinoma
(127 unread)
Adenoid Cystic Carcinoma
(705 unread)
Adrenal Gland Cancer
(2666 unread)
Ampulla Of Vater
(958 unread)
Anal Cancer
(3342 unread)
Angiosarcoma
(1002 unread)
Appendix Cancer
(438 unread)
Bile Duct Cancer
(3816 unread)
Brain and CNS
(4383 unread)
Carcinoid
(1375 unread)
Endocrine/Neuroendocrine
(3718 unread)
Gall Bladder Cancer
(1447 unread)
Hemangioendothelioma
(317 unread)
Hepatoblastoma
(515 unread)
Pancreas
(425 unread)
Phyllodes
(259 unread)
PMP and Mucinous Tumors
(314 unread)
Rhabdomyosarcoma
(1171 unread)
Sarcoma
(5173 unread)
Google - Angiosarcoma (100 unread)
-
$-0.19 EPS Expected for TRACON Pharmaceuticals, Inc. (TCON) - The MAK Daily
Posted: July 14th, 2019, 2:43am GMT
$-0.19 EPS Expected for TRACON Pharmaceuticals, Inc. (TCON) The MAK Daily -
$-0.44 EPS Expected for Athenex, Inc. (ATNX) - Invest Tribune
Posted: July 14th, 2019, 10:28pm GMT
$-0.44 EPS Expected for Athenex, Inc. (ATNX) Invest TribuneAnalysts expect Athenex, Inc. (NASDAQ:ATNX) to report $-0.44 EPS on August, 13.They anticipate $0.14 EPS change or 24.14 % from last quarter's $-0.58 EPS.
-
EPS for Athenex, Inc. (ATNX) Expected At $-0.44 - The MAK Daily
Posted: July 13th, 2019, 8:50pm GMT
EPS for Athenex, Inc. (ATNX) Expected At $-0.44 The MAK DailyAnalysts expect Athenex, Inc. (NASDAQ:ATNX) to report $-0.44 EPS on August, 13.They anticipate $0.14 EPS change or 24.14 % from last quarter's $-0.58 EPS.
-
Actinium Pharmaceuticals Inc. (ATNM)'s Financial Results Comparing With TRACON Pharmaceuticals Inc. (NASDAQ:TCON) - Stocks Beat
Posted: July 13th, 2019, 12:50am GMT
Actinium Pharmaceuticals Inc. (ATNM)'s Financial Results Comparing With TRACON Pharmaceuticals Inc. (NASDAQ:TCON) Stocks BeatAs Biotechnology businesses, Actinium Pharmaceuticals Inc. (NYSEAMERICAN:ATNM) and TRACON Pharmaceuticals Inc. (NASDAQ:TCON), are affected by ...
-
$-0.19 EPS Expected for TRACON Pharmaceuticals, Inc. (TCON) - The MAK Daily
Posted: July 12th, 2019, 3:58am GMT
$-0.19 EPS Expected for TRACON Pharmaceuticals, Inc. (TCON) The MAK DailyAnalysts expect TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) to report $-0.19 EPS on August, 14.They anticipate $0.14 EPS change or 42.42 % from last ...
-
Angiosarcomas Treatment Market Estimated Witness a Phenomenal Growth by 2026 - TechnoBleak
Posted: July 12th, 2019, 1:06am GMT
Angiosarcomas Treatment Market Estimated Witness a Phenomenal Growth by 2026 TechnoBleakThe “Angiosarcomas Treatment Market Industry Report and Forecast Evaluation till 2026” far and wide is a standout amongst the most blossoming and ...
-
EPS for Athenex, Inc. (ATNX) Expected At $-0.44 - FinanceRecorder
Posted: July 12th, 2019, 10:19pm GMT
EPS for Athenex, Inc. (ATNX) Expected At $-0.44 FinanceRecorderAnalysts expect Athenex, Inc. (NASDAQ:ATNX) to report $-0.44 EPS on August, 13.They anticipate $0.14 EPS change or 24.14 % from last quarter's $-0.58 EPS.
-
Reviewing Curis Inc. (CRIS)'s and TRACON Pharmaceuticals Inc. (NASDAQ:TCON)'s results - Stocks Beat
Posted: July 11th, 2019, 7:20pm GMT
Reviewing Curis Inc. (CRIS)'s and TRACON Pharmaceuticals Inc. (NASDAQ:TCON)'s results Stocks BeatAs Biotechnology companies, Curis Inc. (NASDAQ:CRIS) and TRACON Pharmaceuticals Inc. (NASDAQ:TCON) are our subject to contrast. And more specifically ...
-
Athenex, Inc. (ATNX) Reaches $20.19 After 4.00% Down Move; Ottawa Bancorp (OTTW) Shorts Down By 62.16% - The EN Herald
Posted: July 11th, 2019, 6:17pm GMT
Athenex, Inc. (ATNX) Reaches $20.19 After 4.00% Down Move; Ottawa Bancorp (OTTW) Shorts Down By 62.16% The EN HeraldOttawa Bancorp Inc (NASDAQ:OTTW) had a decrease of 62.16% in short interest. OTTW's SI was 1,400 shares in July as released by FINRA. Its down 62.16% ...
-
Angiosarcoma 2019 Pipeline Analysis, Drug Overview, Therapeutic Assessment, Company Profile, Emerging Players, Potential Partners, Mergers and Acquisitions - PortNews24
Posted: July 11th, 2019, 7:51am GMT
Angiosarcoma 2019 Pipeline Analysis, Drug Overview, Therapeutic Assessment, Company Profile, Emerging Players, Potential Partners, Mergers and Acquisitions PortNews24“Angiosarcoma-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this Indication. A key objective of the report is ...
-
Angiosarcomas Treatment Market, 2018-2026 – Industry Applications,Market Share, Segmentation, Company Share: Coherent Market Insights - Truth Daily Mirror
Posted: July 11th, 2019, 4:40am GMT
Angiosarcomas Treatment Market, 2018-2026 – Industry Applications,Market Share, Segmentation, Company Share: Coherent Market Insights Truth Daily MirrorCoherent Market Insights released a new market study on 2018-2026 Angiosarcomas Treatment Market with 100+ market data Tables, Pie Chat, Graphs ...
-
Contrasting of TRACON Pharmaceuticals Inc. (TCON) and Biofrontera AG (NASDAQ:BFRA) - Stocks Beat
Posted: July 10th, 2019, 2:54am GMT
Contrasting of TRACON Pharmaceuticals Inc. (TCON) and Biofrontera AG (NASDAQ:BFRA) Stocks BeatAs Biotechnology businesses, TRACON Pharmaceuticals Inc. (NASDAQ:TCON) and Biofrontera AG (NASDAQ:BFRA), are affected by contrast. This especially ...
-
Angiosarcomas Treatment Market Benefit and Volume 2018 with Status and Prospect to 2026 - Veteran's Weekly
Posted: July 10th, 2019, 11:25pm GMT
Angiosarcomas Treatment Market Benefit and Volume 2018 with Status and Prospect to 2026 Veteran's WeeklyThe Angiosarcomas Treatment Market Report conveys the clean expounded structure of the Market including every single business-related data of the market at ...
-
Contrasting of Eidos Therapeutics Inc. (EIDX) and TRACON Pharmaceuticals Inc. (NASDAQ:TCON) - The EN Herald
Posted: July 9th, 2019, 4:20am GMT
Contrasting of Eidos Therapeutics Inc. (EIDX) and TRACON Pharmaceuticals Inc. (NASDAQ:TCON) The EN HeraldThis is therefore a contrasting of the analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership in Eidos.
-
Angiosarcomas Treatment Market Key Players' Profile and Industry Analysis to 2024 – Pfizer, Inc., Genentech, Bayer Healthcare - PortNews24
Posted: July 8th, 2019, 4:13am GMT
Angiosarcomas Treatment Market Key Players' Profile and Industry Analysis to 2024 – Pfizer, Inc., Genentech, Bayer Healthcare PortNews24Rare and clinically highly variable, Sarcoma is a type of cancer that originates from mesenchymal cells transformation. Sarcoma defines as the major tumors, ...
-
Global Dried Yeast Market 2019 By Manufacturers, Regions, Type And Application, Forecast To 2024 - PortNews24
Posted: July 8th, 2019, 4:12am GMT
Global Dried Yeast Market 2019 By Manufacturers, Regions, Type And Application, Forecast To 2024 PortNews24Global Dried Yeast Reports presents a pin-point breakdown of Dried Yeast Industry based on type, applications, and research regions. The market drivers ...
-
Angiosarcomas Treatment Market - Veteran's Weekly
Posted: July 8th, 2019, 3:26am GMT
Angiosarcomas Treatment Market 2026 Growth Trends by Manufacturers, Regions, Type and Application, Forecast Veteran's WeeklyAngiosarcoma is a rare cancer of the inner lining of blood vessels, which occur in any area of the body, including the skin, breast, liver, spleen, and deep tissue ...
-
Angiosarcomas Treatment Market Will Play Crucial Role For Various Industries Growth In Near Future!! - Coherent Magazine
Posted: July 8th, 2019, 11:25pm GMT
Angiosarcomas Treatment Market Will Play Crucial Role For Various Industries Growth In Near Future!! Coherent MagazineAn extensive study offering forecast assessment on Angiosarcomas Treatment Market has been broadcasted. By correlating the historical data with key market ...
-
Legacy of woman who battled cancer lives on in McDonald - WYTV
Posted: July 7th, 2019, 6:38pm GMT
Legacy of woman who battled cancer lives on in McDonald WYTVMCDONALD, Ohio (WYTV) – After Cindy Green Robinson was diagnosed with angiosarcoma in 2016, she made sure the rare cancer would not define her.
-
Tracon Pharmaceuticals Inc (NASDAQ:TCON) Stock Is Shorted More - The MAK Daily
Posted: July 7th, 2019, 4:46pm GMT
Tracon Pharmaceuticals Inc (NASDAQ:TCON) Stock Is Shorted More The MAK DailyThe stock of Tracon Pharmaceuticals Inc (NASDAQ:TCON) registered an increase of 73.68% in short interest. TCON's total short interest was 430200 shares in.
-
Tracon Pharmaceuticals Inc (NASDAQ:TCON) Shorted Shares Increased By 73.68% - Invest Tribune
Posted: July 7th, 2019, 4:29pm GMT
Tracon Pharmaceuticals Inc (NASDAQ:TCON) Shorted Shares Increased By 73.68% Invest TribuneThe stock of Tracon Pharmaceuticals Inc (NASDAQ:TCON) registered an increase of 73.68% in short interest. TCON's total short interest was 430200 shares in.
-
TRACON Pharmaceuticals Inc. (TCON) and CohBar Inc. (NASDAQ:CWBR) Comparing side by side - Stocks Beat
Posted: July 7th, 2019, 10:11pm GMT
TRACON Pharmaceuticals Inc. (TCON) and CohBar Inc. (NASDAQ:CWBR) Comparing side by side Stocks BeatWe are comparing TRACON Pharmaceuticals Inc. (NASDAQ:TCON) and CohBar Inc. (NASDAQ:CWBR) on their institutional ownership, profitability, risk, analyst ...
-
Reviewing TRACON Pharmaceuticals Inc. (TCON)'s and Forty Seven Inc. (NASDAQ:FTSV)'s results - Stocks Beat
Posted: July 6th, 2019, 3:18pm GMT
Reviewing TRACON Pharmaceuticals Inc. (TCON)'s and Forty Seven Inc. (NASDAQ:FTSV)'s results Stocks BeatTRACON Pharmaceuticals Inc. (NASDAQ:TCON) and Forty Seven Inc. (NASDAQ:FTSV), both competing one another are Biotechnology companies. We will ...
-
9-year-old shaves heads to fight cancer - Jacksonville Daily News
Posted: July 5th, 2019, 5:29pm GMT
9-year-old shaves heads to fight cancer Jacksonville Daily NewsThe buzzing sound of clippers filled the air, shaving away every strand of hair on the heads of anyone looking to make a big stand for a cause very close to one ...
-
Is Athenex, Inc. (ATNX)'s Fuel For Real? The Stock Just Increased Again - Invest Tribune
Posted: July 5th, 2019, 3:43pm GMT
Is Athenex, Inc. (ATNX)'s Fuel For Real? The Stock Just Increased Again Invest TribuneThe stock of Athenex, Inc. (NASDAQ:ATNX) is a huge mover today! The stock increased 2.21% or $0.41 during the last trading session, reaching $19.18. About.
-
Orphan Drugs Market Demand, Competitive Analysis 2014-2022 and Key Players – AbbVie , Aegerion Pharmaceuticals, Bristol-Myers Squibb Company , Celgene Corporation - Amazing Newspaper
Posted: July 5th, 2019, 8:38am GMT
Orphan Drugs Market Demand, Competitive Analysis 2014-2022 and Key Players – AbbVie , Aegerion Pharmaceuticals, Bristol-Myers Squibb Company , Celgene Corporation Amazing NewspaperThe pharmaceutical agents that are administered to treat, diagnose, and prevent life-threatening diseases (rare diseases) are known as orphan drugs.
-
What's in TRACON Pharmaceuticals, Inc. (TCON) After Forming Bearish Multiple Bottom? - Invest Tribune
Posted: July 5th, 2019, 8:21am GMT
What's in TRACON Pharmaceuticals, Inc. (TCON) After Forming Bearish Multiple Bottom? Invest TribuneThe stock of TRACON Pharmaceuticals, Inc. (TCON) shows a multiple bottoms pattern with $0.57 target or 8.00 % below today's $0.62 share price.
-
Zacks: Brokerages Anticipate TRACON Pharmaceuticals Inc (NASDAQ:TCON) Will Announce Earnings of -$0.19 Per Share - Riverton Roll
Posted: July 4th, 2019, 9:20am GMT
Zacks: Brokerages Anticipate TRACON Pharmaceuticals Inc (NASDAQ:TCON) Will Announce Earnings of -$0.19 Per Share Riverton RollBrokerages expect that TRACON Pharmaceuticals Inc (NASDAQ:TCON) will post earnings of ($0.19) per share for the current quarter, according to Zacks ...
-
Angiosarcomas Treatment Market Benefit and Volume 2018 with Status and Prospect to 2026 - AppWebRadar
Posted: July 4th, 2019, 3:47am GMT
Angiosarcomas Treatment Market Benefit and Volume 2018 with Status and Prospect to 2026 AppWebRadarAngiosarcomas Treatment Market Report presents a vigorous vision to conclude and research market size, market scope and competitive environment.
-
Schnitzer Steel Industries, Inc. (SCHN) Reaches $24.39 After 9.00% Down Move; Athenex (ATNX) Sellers Decreased By 2.6% Their Shorts - The EN Herald
Posted: July 3rd, 2019, 5:19pm GMT
Schnitzer Steel Industries, Inc. (SCHN) Reaches $24.39 After 9.00% Down Move; Athenex (ATNX) Sellers Decreased By 2.6% Their Shorts The EN HeraldAthenex Inc (NASDAQ:ATNX) had a decrease of 2.6% in short interest. ATNX's SI was 5.60M shares in July as released by FINRA. Its down 2.6% from 5.75 ...
-
Schnitzer Steel Industries, Inc. (SCHN) Reaches $24.39 After 9.00% Down Move; Athenex (ATNX) Sellers Decreased By 2.6% Their Shorts - The EN Herald
Posted: July 3rd, 2019, 5:19pm GMT
Schnitzer Steel Industries, Inc. (SCHN) Reaches $24.39 After 9.00% Down Move; Athenex (ATNX) Sellers Decreased By 2.6% Their Shorts The EN HeraldThe stock of Schnitzer Steel Industries, Inc. (NASDAQ:SCHN) is a huge mover today! The stock decreased 8.38% or $2.23 during the last trading session, ...
-
Is Buying Athenex Inc (NASDAQ:ATNX), Having Lower Short Interest a Winning Strategy? - Invest Tribune
Posted: July 3rd, 2019, 11:32am GMT
Is Buying Athenex Inc (NASDAQ:ATNX), Having Lower Short Interest a Winning Strategy? Invest TribuneThe stock of Athenex Inc (NASDAQ:ATNX) registered a decrease of 2.6% in short interest. ATNX's total short interest was 5.60M shares in July as published by.
-
Reviewing TRACON Pharmaceuticals Inc. (TCON)'s and Liquidia Technologies Inc. (NASDAQ:LQDA)'s results - Stocks Beat
Posted: July 3rd, 2019, 3:11am GMT
Reviewing TRACON Pharmaceuticals Inc. (TCON)'s and Liquidia Technologies Inc. (NASDAQ:LQDA)'s results Stocks BeatTRACON Pharmaceuticals Inc. (NASDAQ:TCON) and Liquidia Technologies Inc. (NASDAQ:LQDA), both competing one another are Biotechnology companies.
-
VEGFR Targeted Therapies and Combinations Emerge for the Treatment of Sarcomas - Targeted Oncology
Posted: July 1st, 2019, 7:04pm GMT
VEGFR Targeted Therapies and Combinations Emerge for the Treatment of Sarcomas Targeted OncologyBased on the ongoing and positive data observed with VEGFR targeted therapies, novel tyrosine kinase inhibitors and those already approved for other disease ...
-
Brokerages Expect TRACON Pharmaceuticals Inc (NASDAQ:TCON) to Post -$0.19 Earnings Per Share - Rockland Register
Posted: July 1st, 2019, 8:36am GMT
Brokerages Expect TRACON Pharmaceuticals Inc (NASDAQ:TCON) to Post -$0.19 Earnings Per Share Rockland RegisterWall Street brokerages predict that TRACON Pharmaceuticals Inc (NASDAQ:TCON) will post earnings per share (EPS) of ($0.19) for the current fiscal quarter, ...
-
TRACON Pharmaceuticals Inc (NASDAQ:TCON) Expected to Announce Earnings of -$0.19 Per Share - Mayfield Recorder
Posted: July 1st, 2019, 8:33am GMT
TRACON Pharmaceuticals Inc (NASDAQ:TCON) Expected to Announce Earnings of -$0.19 Per Share Mayfield RecorderAnalysts expect TRACON Pharmaceuticals Inc (NASDAQ:TCON) to report earnings per share (EPS) of ($0.19) for the current fiscal quarter, Zacks Investment ...
-
Athenex, Inc. (ATNX) Reaches $19.80 After 9.00% Up Move; CMS Energy (CMS) Had 0 Bullish Analysts - The EN Herald
Posted: June 30th, 2019, 3:58pm GMT
Athenex, Inc. (ATNX) Reaches $19.80 After 9.00% Up Move; CMS Energy (CMS) Had 0 Bullish Analysts The EN HeraldThe stock of Athenex, Inc. (NASDAQ:ATNX) is a huge mover today! The stock increased 7.67% or $1.41 during the last trading session, reaching $19.8.
-
TRACON Pharmaceuticals (NASDAQ:TCON) Stock Price Down 13.9% - Rockland Register
Posted: June 30th, 2019, 2:23pm GMT
TRACON Pharmaceuticals (NASDAQ:TCON) Stock Price Down 13.9% Rockland RegisterTRACON Pharmaceuticals Inc (NASDAQ:TCON) was down 13.9% during mid-day trading on Friday . The company traded as low as $0.67 and last traded at ...
-
-$0.19 EPS Expected for TRACON Pharmaceuticals Inc (NASDAQ:TCON) This Quarter - Mayfield Recorder
Posted: June 30th, 2019, 1:43pm GMT
-$0.19 EPS Expected for TRACON Pharmaceuticals Inc (NASDAQ:TCON) This Quarter Mayfield RecorderAnalysts expect TRACON Pharmaceuticals Inc (NASDAQ:TCON) to announce ($0.19) earnings per share (EPS) for the current quarter, Zacks Investment ...
-
Reviewing TRACON Pharmaceuticals Inc. (TCON)'s and Rexahn Pharmaceuticals Inc. (:)'s results - The NBO News
Posted: June 30th, 2019, 6:44am GMT
Reviewing TRACON Pharmaceuticals Inc. (TCON)'s and Rexahn Pharmaceuticals Inc. (:)'s results The NBO NewsThis is therefore a contrasting of the profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation in TRACON.
-
TRACON Pharmaceuticals (NASDAQ:TCON) Shares Down 13.9% - Trent Times
Posted: June 29th, 2019, 1:24am GMT
TRACON Pharmaceuticals (NASDAQ:TCON) Shares Down 13.9% Trent TimesTRACON Pharmaceuticals Inc (NASDAQ:TCON) was down 13.9% during trading on Friday . The stock traded as low as $0.67 and last traded at $0.68.
-
Gov. Abbot signs bill to allow creation of 'Burn Pit Registry' - KXXV News Channel 25
Posted: June 28th, 2019, 9:48pm GMT
Gov. Abbot signs bill to allow creation of 'Burn Pit Registry' KXXV News Channel 25A new Burn Pit Registry in the State of Texas aims to create awareness and resources for soldiers exposed to toxins from the pits while they serve.
-
Burlesque evening at Deeping Sports and Social Club raises more than £5000 for Sarcoma UK - Stamford Mercury
Posted: June 28th, 2019, 10:00am GMT
Burlesque evening at Deeping Sports and Social Club raises more than £5000 for Sarcoma UK Stamford MercurySisters Lizzie Hudson, 38 and Sam Haselgrove, 40 staged the event on June 8 at Deeping Sports and Social Club.
-
Angiosarcomas Treatment Market to Record an Impressive Growth Rate by 2026 - Ace Newz
Posted: June 28th, 2019, 3:39am GMT
Angiosarcomas Treatment Market to Record an Impressive Growth Rate by 2026 Ace NewzThe recently published report called “Global Angiosarcomas Treatment Market 2018 – 2026” is a fundamental study carried out by the experts with a perspective ...
-
Reviewing Aquestive Therapeutics Inc. (AQST)'s and TRACON Pharmaceuticals Inc. (NASDAQ:TCON)'s results - Stocks Beat
Posted: June 27th, 2019, 8:36pm GMT
Reviewing Aquestive Therapeutics Inc. (AQST)'s and TRACON Pharmaceuticals Inc. (NASDAQ:TCON)'s results Stocks BeatThis is a contrast between Aquestive Therapeutics Inc. (NASDAQ:AQST) and TRACON Pharmaceuticals Inc. (NASDAQ:TCON) based on their risk, analyst.
-
Orphan Drugs Market to Witness High Growth in near future: AbbVie Inc., Aegerion Pharmaceuticals Inc., Bristol-Myers Squibb Company - Market Mirror
Posted: June 27th, 2019, 3:08pm GMT
Orphan Drugs Market to Witness High Growth in near future: AbbVie Inc., Aegerion Pharmaceuticals Inc., Bristol-Myers Squibb Company Market MirrorOrphan Drugs Market to Witness High Growth in near future: AbbVie Inc., Aegerion Pharmaceuticals Inc., Bristol-Myers Squibb Company. by Allied Market ...
-
Soft Tissue Sarcoma Treatment Market to Witness Comprehensive Growth by 2025 - Technology Market
Posted: June 27th, 2019, 6:40am GMT
Soft Tissue Sarcoma Treatment Market to Witness Comprehensive Growth by 2025 Technology MarketSarcoma are the type of cancer that develops from tissues such as nerves, muscles, fats, blood vessels and deep skin tissues. It occurs in the blood vessels, ...
-
Synthorx Inc. (THOR)'s Financial Results Comparing With TRACON Pharmaceuticals Inc. (NASDAQ:TCON) - Stocks Beat
Posted: June 27th, 2019, 3:49am GMT
Synthorx Inc. (THOR)'s Financial Results Comparing With TRACON Pharmaceuticals Inc. (NASDAQ:TCON) Stocks BeatWe are contrasting Synthorx Inc. (NASDAQ:THOR) and TRACON Pharmaceuticals Inc. (NASDAQ:TCON) on their analyst recommendations, profitability, risk, ...
-
Reviewing Navidea Biopharmaceuticals Inc. (NAVB)'s and TRACON Pharmaceuticals Inc. (NASDAQ:TCON)'s results - Stocks Beat
Posted: June 27th, 2019, 2:49am GMT
Reviewing Navidea Biopharmaceuticals Inc. (NAVB)'s and TRACON Pharmaceuticals Inc. (NASDAQ:TCON)'s results Stocks BeatThis is a contrast between Navidea Biopharmaceuticals Inc. (NYSEAMERICAN:NAVB) and TRACON Pharmaceuticals Inc. (NASDAQ:TCON) based on their ...
-
Reviewing TrovaGene Inc. (TROV)'s and TRACON Pharmaceuticals Inc. (NASDAQ:TCON)'s results - Stocks Beat
Posted: June 27th, 2019, 2:44am GMT
Reviewing TrovaGene Inc. (TROV)'s and TRACON Pharmaceuticals Inc. (NASDAQ:TCON)'s results Stocks BeatBoth TrovaGene Inc. (NASDAQ:TROV) and TRACON Pharmaceuticals Inc. (NASDAQ:TCON) are Biotechnology companies, competing one another. We will ...
-
TRACON Pharmaceuticals Inc. (TCON)'s Financial Results Comparing With Aptorum Group Limited (NASDAQ:APM) - Stocks Beat
Posted: June 27th, 2019, 12:26am GMT
TRACON Pharmaceuticals Inc. (TCON)'s Financial Results Comparing With Aptorum Group Limited (NASDAQ:APM) Stocks BeatTRACON Pharmaceuticals Inc. (NASDAQ:TCON) and Aptorum Group Limited (NASDAQ:APM), are influenced by contrast since they are both players in the ...
-
Can-Fite BioPharma Ltd. (CANF)'s Financial Results Comparing With TRACON Pharmaceuticals Inc. (NASDAQ:TCON) - The EN Herald
Posted: June 27th, 2019, 11:07pm GMT
Can-Fite BioPharma Ltd. (CANF)'s Financial Results Comparing With TRACON Pharmaceuticals Inc. (NASDAQ:TCON) The EN HeraldWe are comparing Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF) and TRACON Pharmaceuticals Inc. (NASDAQ:TCON) on their risk, analyst ...
-
Is Buying Tracon Pharmaceuticals Inc (NASDAQ:TCON) Here Good Idea? - The Altcoin Mercury
Posted: June 26th, 2019, 6:53pm GMT
Is Buying Tracon Pharmaceuticals Inc (NASDAQ:TCON) Here Good Idea? The Altcoin MercuryThe stock of Tracon Pharmaceuticals Inc (NASDAQ:TCON) registered an increase of 73.68% in short interest. TCON's total short interest was 430200 shares in.
-
Angiosarcomas Treatment Market Provides An In-Depth Insight Of Sales And Trends Forecast To 2026 - Veteran's Vista
Posted: June 26th, 2019, 8:33am GMT
Angiosarcomas Treatment Market Provides An In-Depth Insight Of Sales And Trends Forecast To 2026 Veteran's VistaAngiosarcoma is a rare cancer of the inner lining of blood vessels, which occur in any area of the body, including the skin, breast, liver, spleen, and deep tissue ...
-
TRACON Pharmaceuticals (NASDAQ:TCON) Trading Up 9.4% - Rockland Register
Posted: June 25th, 2019, 8:21am GMT
TRACON Pharmaceuticals (NASDAQ:TCON) Trading Up 9.4% Rockland RegisterShares of TRACON Pharmaceuticals Inc (NASDAQ:TCON) were up 9.4% on Monday . The stock traded as high as $0.74 and last traded at $0.70. Approximately ...
-
Angiosarcomas Treatment Market is Expected to Demonstrate the Strongest Growth Rate by 2026 - Truth Daily Mirror
Posted: June 25th, 2019, 6:06am GMT
Angiosarcomas Treatment Market is Expected to Demonstrate the Strongest Growth Rate by 2026 Truth Daily MirrorThe “Angiosarcomas Treatment” Market: Global Industry Perspective, Comprehensive Analysis and Forecast, 2019 – 2026 report offers a thought with ...
-
Comparison of TRACON Pharmaceuticals Inc. (TCON) and Emergent BioSolutions Inc. (NYSE:EBS) - Stocks Beat
Posted: June 25th, 2019, 11:30pm GMT
Comparison of TRACON Pharmaceuticals Inc. (TCON) and Emergent BioSolutions Inc. (NYSE:EBS) Stocks BeatWe are contrasting TRACON Pharmaceuticals Inc. (NASDAQ:TCON) and Emergent BioSolutions Inc. (NYSE:EBS) on their dividends, institutional ownership, ...
-
Orphan Drugs Market Worldwide Industry Opportunities, Sales, Revenue, Outlook and Forecast to 2022 – AbbVie, Aegerion Pharmaceuticals, Bristol-Myers Squibb Company, Celgene - Honest Version
Posted: June 24th, 2019, 8:13am GMT
Orphan Drugs Market Worldwide Industry Opportunities, Sales, Revenue, Outlook and Forecast to 2022 – AbbVie, Aegerion Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Honest VersionThe report on “Orphan Drugs Market” will help Major Players and the new entrants to understand scrutinize the market in detail. This information will encourage ...
-
Reviewing TRACON Pharmaceuticals Inc. (TCON)'s and ImmunoGen Inc. (NASDAQ:IMGN)'s results - Stocks Beat
Posted: June 24th, 2019, 1:01am GMT
Reviewing TRACON Pharmaceuticals Inc. (TCON)'s and ImmunoGen Inc. (NASDAQ:IMGN)'s results Stocks BeatTRACON Pharmaceuticals Inc. (NASDAQ:TCON) and ImmunoGen Inc. (NASDAQ:IMGN) are two firms in the Biotechnology that compete against each other.
-
Contrasting of TRACON Pharmaceuticals Inc. (TCON) and BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) - Stocks Beat
Posted: June 23rd, 2019, 9:17pm GMT
Contrasting of TRACON Pharmaceuticals Inc. (TCON) and BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) Stocks BeatThis is a contrast between TRACON Pharmaceuticals Inc. (NASDAQ:TCON) and BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) based on their dividends, ...
-
-$0.19 EPS Expected for TRACON Pharmaceuticals Inc (TCON) This Quarter - Sundance Herald
Posted: June 23rd, 2019, 2:16am GMT
-$0.19 EPS Expected for TRACON Pharmaceuticals Inc (TCON) This Quarter Sundance HeraldEquities research analysts predict that TRACON Pharmaceuticals Inc (NASDAQ:TCON) will announce ($0.19) earnings per share for the current fiscal quarter, ...
-
-$0.19 EPS Expected for TRACON Pharmaceuticals Inc (NASDAQ:TCON) This Quarter - Mayfield Recorder
Posted: June 22nd, 2019, 7:45pm GMT
-$0.19 EPS Expected for TRACON Pharmaceuticals Inc (NASDAQ:TCON) This Quarter Mayfield RecorderAnalysts expect TRACON Pharmaceuticals Inc (NASDAQ:TCON) to announce ($0.19) earnings per share (EPS) for the current quarter, Zacks Investment ...
-
Soft Tissue Sarcoma Treatment Market Is Projected To Grow At A Healthy Rate Over The Next Seven Years - Market Mirror
Posted: June 22nd, 2019, 9:24am GMT
Soft Tissue Sarcoma Treatment Market Is Projected To Grow At A Healthy Rate Over The Next Seven Years Market MirrorSoft Tissue Sarcoma Treatment Market Is Projected To Grow At A Healthy Rate Over The Next Seven Years. by mangesh.k@futuremarketinsights.com ...
-
Nicolet Advisory Services LLC Acquires New Stake in TRACON Pharmaceuticals Inc (NASDAQ:TCON) - Tech Know Bits
Posted: June 22nd, 2019, 11:43pm GMT
Nicolet Advisory Services LLC Acquires New Stake in TRACON Pharmaceuticals Inc (NASDAQ:TCON) Tech Know BitsNicolet Advisory Services LLC acquired a new stake in shares of TRACON Pharmaceuticals Inc (NASDAQ:TCON) in the first quarter, according to the company ...
-
Maxar Technologies Inc. (MAXR) Reaches $7.40 After 8.00% Down Move; Athenex (ATNX) Sellers Decreased By 2.6% Their Shorts - The NBO News
Posted: June 21st, 2019, 2:41pm GMT
Maxar Technologies Inc. (MAXR) Reaches $7.40 After 8.00% Down Move; Athenex (ATNX) Sellers Decreased By 2.6% Their Shorts The NBO NewsThe stock of Maxar Technologies Inc. (NYSE:MAXR) is a huge mover today! The stock decreased 0.54% or $0.04 during the last trading session, reaching $7.4.
-
TRACON Pharmaceuticals (NASDAQ:TCON) Share Price Crosses Above 50-Day Moving Average of $0.68 - Rockland Register
Posted: June 21st, 2019, 12:05pm GMT
TRACON Pharmaceuticals (NASDAQ:TCON) Share Price Crosses Above 50-Day Moving Average of $0.68 Rockland RegisterTRACON Pharmaceuticals Inc (NASDAQ:TCON) passed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving ...
-
Ultimate Growth of Angiosarcoma Market is Estimated to Grow Incredible CAGR till 2023 - Fanancials
Posted: June 21st, 2019, 5:20am GMT
Ultimate Growth of Angiosarcoma Market is Estimated to Grow Incredible CAGR till 2023 FanancialsThe exclusive research report on the Global Angiosarcoma Market 2019 examines the market in detail along with focusing on significant market dynamics for the ...
-
TRACON Pharmaceuticals Inc. (TCON)'s Financial Results Comparing With Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) - Stocks Beat
Posted: June 20th, 2019, 9:22pm GMT
TRACON Pharmaceuticals Inc. (TCON)'s Financial Results Comparing With Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) Stocks BeatTRACON Pharmaceuticals Inc. (NASDAQ:TCON) and Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) have been rivals in the Biotechnology for quite some ...
-
Abeona Therapeutics Inc. (ABEO)'s Financial Results Comparing With TRACON Pharmaceuticals Inc. (NASDAQ:TCON) - Stocks Beat
Posted: June 20th, 2019, 5:36pm GMT
Abeona Therapeutics Inc. (ABEO)'s Financial Results Comparing With TRACON Pharmaceuticals Inc. (NASDAQ:TCON) Stocks BeatBoth Abeona Therapeutics Inc. (NASDAQ:ABEO) and TRACON Pharmaceuticals Inc. (NASDAQ:TCON) are Biotechnology companies, competing one another.
-
Cynthia Green Robinson Obituary - WKBN.com
Posted: June 20th, 2019, 1:46pm GMT
Cynthia Green Robinson Obituary WKBN.comMcDONALD, Ohio (MyValleyTributes) – Cynthia Green Robinson (Cindy, Momma, Crazy Aunt C, Weezie), 34, of McDonald, Ohio died Tuesday, June 18, 2019 ...
-
Cynthia Green Robinson Obituary - WKBN.com
Posted: June 20th, 2019, 5:00am GMT
Cynthia Green Robinson Obituary WKBN.comMcDONALD, Ohio (MyValleyTributes) – Cynthia Green Robinson (Cindy, Momma, Crazy Aunt C, Weezie), 34, of McDonald, Ohio died Tuesday, June 18, 2019 ...
-
Reviewing TRACON Pharmaceuticals Inc. (TCON)'s and Heat Biologics Inc. (NASDAQ:HTBX)'s results - Stocks Beat
Posted: June 18th, 2019, 12:21am GMT
Reviewing TRACON Pharmaceuticals Inc. (TCON)'s and Heat Biologics Inc. (NASDAQ:HTBX)'s results Stocks BeatWe are comparing TRACON Pharmaceuticals Inc. (NASDAQ:TCON) and Heat Biologics Inc. (NASDAQ:HTBX) on their dividends, analyst recommendations, ...
-
Comparing of TRACON Pharmaceuticals Inc. (TCON) and Acasti Pharma Inc. (NASDAQ:ACST) - Stocks Beat
Posted: June 18th, 2019, 12:01am GMT
Comparing of TRACON Pharmaceuticals Inc. (TCON) and Acasti Pharma Inc. (NASDAQ:ACST) Stocks BeatTRACON Pharmaceuticals Inc. (NASDAQ:TCON) and Acasti Pharma Inc. (NASDAQ:ACST), are influenced by contrast since they are both players in the ...
-
Angiosarcomas Treatment Market Influencing Factors by Top Companies - Business Herald
Posted: June 18th, 2019, 10:40pm GMT
Angiosarcomas Treatment Market Influencing Factors by Top Companies Business HeraldAngiosarcomas Treatment Market: The report provides a valuable source of insightful data for business strategists and competitive analysis of Angiosarcomas ...
-
Comparing of TRACON Pharmaceuticals Inc. (TCON) and InflaRx NV (NASDAQ:IFRX) - The NBO News
Posted: June 17th, 2019, 7:26pm GMT
Comparing of TRACON Pharmaceuticals Inc. (TCON) and InflaRx NV (NASDAQ:IFRX) The NBO NewsThis is a contrast between TRACON Pharmaceuticals Inc. (NASDAQ:TCON) and InflaRx N.V. (NASDAQ:IFRX) based on their risk, analyst recommendations,
-
Harvard Scientists Make 'Landmark' Discovery in Synthesizing Anti-Cancer Molecules Found in Sea Sponges - Gizmodo
Posted: June 17th, 2019, 5:20pm GMT
Harvard Scientists Make 'Landmark' Discovery in Synthesizing Anti-Cancer Molecules Found in Sea Sponges GizmodoHarvard and Japanese scientists say they've made a “landmark” discovery in cancer drug development. In a new study published Monday, they say they have ...
-
A Reversal for Athenex, Inc. (ATNX) Is Not Near. The Stock Declines Again - Invest Tribune
Posted: June 17th, 2019, 4:32pm GMT
A Reversal for Athenex, Inc. (ATNX) Is Not Near. The Stock Declines Again Invest TribuneThe stock of Athenex, Inc. (NASDAQ:ATNX) is a huge mover today! The stock decreased 2.08% or $0.37 during the last trading session, reaching $17.43. About.
-
Athenex, Inc. (ATNX) Reaches $17.32 After 7.00% Down Move; Darling International (DAR) Has 1.05 Sentiment - The NBO News
Posted: June 17th, 2019, 4:28pm GMT
Athenex, Inc. (ATNX) Reaches $17.32 After 7.00% Down Move; Darling International (DAR) Has 1.05 Sentiment The NBO NewsThe stock of Athenex, Inc. (NASDAQ:ATNX) is a huge mover today! The stock decreased 2.70% or $0.48 during the last trading session, reaching $17.32.
-
Comparing of TRACON Pharmaceuticals Inc. (TCON) and Trevena Inc. (NASDAQ:TRVN) - Stocks Beat
Posted: June 17th, 2019, 10:52am GMT
Comparing of TRACON Pharmaceuticals Inc. (TCON) and Trevena Inc. (NASDAQ:TRVN) Stocks BeatAs Biotechnology businesses, TRACON Pharmaceuticals Inc. (NASDAQ:TCON) and Trevena Inc. (NASDAQ:TRVN), are affected by compare. This especially ...
-
What's in Tracon Pharmaceuticals Inc (NASDAQ:TCON) After Rise in Shorted Shares? - The MAK Daily
Posted: June 16th, 2019, 4:57pm GMT
What's in Tracon Pharmaceuticals Inc (NASDAQ:TCON) After Rise in Shorted Shares? The MAK DailyThe stock of Tracon Pharmaceuticals Inc (NASDAQ:TCON) registered an increase of 73.68% in short interest. TCON's total short interest was 430200 shares in.
-
Hundreds gather for hope, raising funds to help cancer patients - Scottsbluff Star Herald
Posted: June 16th, 2019, 4:00am GMT
Hundreds gather for hope, raising funds to help cancer patients Scottsbluff Star HeraldVolunteers at the Festival of Hope sported T-shirts, some red, some white, emblazoned with a saying, “Hope is a universal language.”
-
-$0.19 EPS Expected for TRACON Pharmaceuticals Inc (NASDAQ:TCON) This Quarter - Mayfield Recorder
Posted: June 15th, 2019, 7:43pm GMT
-$0.19 EPS Expected for TRACON Pharmaceuticals Inc (NASDAQ:TCON) This Quarter Mayfield RecorderAnalysts expect TRACON Pharmaceuticals Inc (NASDAQ:TCON) to announce ($0.19) earnings per share (EPS) for the current quarter, Zacks Investment ...
-
Light the Community - Jackson County Newspapers
Posted: June 15th, 2019, 1:55am GMT
Light the Community Jackson County NewspapersDinwiddie neighbors get together to raise funds for local families' medical expenses.
-
Light the Community - Keyser Mineral Daily News Tribune
Posted: June 15th, 2019, 1:54am GMT
Light the Community Keyser Mineral Daily News TribuneDinwiddie neighbors get together to raise funds for local families' medical expenses.
-
Neptune Wellness Solutions Inc. (NEPT) and TRACON Pharmaceuticals Inc. (NASDAQ:TCON) Comparison side by side - Stocks Beat
Posted: June 15th, 2019, 10:24pm GMT
Neptune Wellness Solutions Inc. (NEPT) and TRACON Pharmaceuticals Inc. (NASDAQ:TCON) Comparison side by side Stocks BeatBoth Neptune Wellness Solutions Inc. (NASDAQ:NEPT) and TRACON Pharmaceuticals Inc. (NASDAQ:TCON) compete on a level playing field in the ...
-
Angiosarcomas Treatment Market Opportunities and Drivers Value Chain and Sales Channels Analysis Forecast 2026 - Forex Tribune
Posted: June 15th, 2019, 10:20pm GMT
Angiosarcomas Treatment Market Opportunities and Drivers Value Chain and Sales Channels Analysis Forecast 2026 Forex TribuneCoherent Market Insights study report on “Angiosarcomas Treatment Market by Size, Scope, Manufacturers, Applications, Types, Regions and Forecast to 2026”.
-
Nicolet Advisory Services LLC Acquires New Position in TRACON Pharmaceuticals Inc (NASDAQ:TCON) - Tech Know Bits
Posted: June 14th, 2019, 5:42am GMT
Nicolet Advisory Services LLC Acquires New Position in TRACON Pharmaceuticals Inc (NASDAQ:TCON) Tech Know BitsNicolet Advisory Services LLC bought a new position in shares of TRACON Pharmaceuticals Inc (NASDAQ:TCON) during the first quarter, according to its most ...
-
Light the Community - Progress Index
Posted: June 14th, 2019, 4:13am GMT
Light the Community Progress IndexCHURCH ROAD — A “Light the Community” fundraising dinner was held last weekend at the residence of Cody and Melissa Watkins to benefit the Gibbs and ...
-
Zacks: Brokerages Expect TRACON Pharmaceuticals Inc (NASDAQ:TCON) to Post -$0.19 EPS - Rockland Register
Posted: June 13th, 2019, 7:33pm GMT
Zacks: Brokerages Expect TRACON Pharmaceuticals Inc (NASDAQ:TCON) to Post -$0.19 EPS Rockland RegisterWall Street brokerages predict that TRACON Pharmaceuticals Inc (NASDAQ:TCON) will post earnings per share (EPS) of ($0.19) for the current fiscal quarter, ...
-
Angiosarcomas Treatment Market Share, Revenue, and Average Price by Manufacturers Shared in a Latest Research Report - Truth Daily Mirror
Posted: June 13th, 2019, 9:03am GMT
Angiosarcomas Treatment Market Share, Revenue, and Average Price by Manufacturers Shared in a Latest Research Report Truth Daily MirrorLatest Industry Research Report On “Angiosarcomas Treatment – Industry Pipeline Insight, 2019” in-depth analysis of the market state and also the competitive ...
-
Could Athenex Inc (NASDAQ:ATNX) See a Reversal After Less Sellers Came In? - Invest Tribune
Posted: June 12th, 2019, 4:53pm GMT
Could Athenex Inc (NASDAQ:ATNX) See a Reversal After Less Sellers Came In? Invest TribuneThe stock of Athenex Inc (NASDAQ:ATNX) registered a decrease of 2.6% in short interest. ATNX's total short interest was 5.60 million shares in June as.
-
Angiosarcomas Treatment Market Exhibits Higher Growth Prospects during 2018-2026 - Veteran's Vista
Posted: June 12th, 2019, 9:11am GMT
Angiosarcomas Treatment Market Exhibits Higher Growth Prospects during 2018-2026 Veteran's VistaAngiosarcoma is a rare cancer of the inner lining of blood vessels, which occur in any area of the body, including the skin, breast, liver, spleen, and deep tissue ...
-
Angiosarcomas Treatment trends - Veteran's Vista
Posted: June 12th, 2019, 9:11am GMT
Angiosarcomas Treatment trends Veteran's VistaAngiosarcomas Treatment Market Provides An In-Depth Insight Of Sales And Trends Forecast To 2026. Posted on June 26, 2019 June 26, 2019 by James Luke.
-
Angiosarcomas Treatment Market - Veteran's Vista
Posted: June 12th, 2019, 9:11am GMT
Angiosarcomas Treatment Market Veteran's VistaAngiosarcomas Treatment Market Provides An In-Depth Insight Of Sales And Trends Forecast To 2026. Posted on June 26, 2019 June 26, 2019 by James Luke.
-
TRACON Pharmaceuticals Inc. (TCON) and Liquidia Technologies Inc. (NASDAQ:LQDA) Comparing side by side - The NBO News
Posted: June 12th, 2019, 11:22pm GMT
TRACON Pharmaceuticals Inc. (TCON) and Liquidia Technologies Inc. (NASDAQ:LQDA) Comparing side by side The NBO NewsWe are contrasting TRACON Pharmaceuticals Inc. (NASDAQ:TCON) and Liquidia Technologies Inc. (NASDAQ:LQDA) on their dividends, institutional ownership ...
-
Tracon Pharmaceuticals Inc (NASDAQ:TCON) Stock Is Shorted More - Invest Tribune
Posted: June 11th, 2019, 3:40pm GMT
Tracon Pharmaceuticals Inc (NASDAQ:TCON) Stock Is Shorted More Invest TribuneThe stock of Tracon Pharmaceuticals Inc (NASDAQ:TCON) registered an increase of 73.68% in short interest. TCON's total short interest was 430200 shares in.
-
Angiosarcomas Treatment Market Prophesied to Grow at a Faster Pace by 2026 - Business Herald
Posted: June 11th, 2019, 9:03am GMT
Angiosarcomas Treatment Market Prophesied to Grow at a Faster Pace by 2026 Business HeraldAngiosarcomas Treatment Market is a professional and detailed report focusing on primary and secondary drivers, market share, key segments and geographic ...
-
Orphan Drugs Market Competitive Analysis 2014-2022 and Key Players – AbbVie , Aegerion Pharmaceuticals, Bristol-Myers Squibb Company , Celgene Corporation - Honest Version
Posted: June 11th, 2019, 7:50am GMT
Orphan Drugs Market Competitive Analysis 2014-2022 and Key Players – AbbVie , Aegerion Pharmaceuticals, Bristol-Myers Squibb Company , Celgene Corporation Honest VersionThe pharmaceutical agents that are administered to treat, diagnose, and prevent life-threatening diseases (rare diseases) are known as orphan drugs.
-
Analysts Anticipate TRACON Pharmaceuticals Inc (TCON) Will Post Earnings of -$0.20 Per Share - Tech Know Bits
Posted: June 11th, 2019, 4:46am GMT
Analysts Anticipate TRACON Pharmaceuticals Inc (TCON) Will Post Earnings of -$0.20 Per Share Tech Know BitsWall Street brokerages forecast that TRACON Pharmaceuticals Inc (NASDAQ:TCON) will post earnings per share (EPS) of ($0.20) for the current quarter, ...
-
Comparing of TRACON Pharmaceuticals Inc. (TCON) and BioXcel Therapeutics Inc. (NASDAQ:BTAI) - The NBO News
Posted: June 10th, 2019, 5:11pm GMT
Comparing of TRACON Pharmaceuticals Inc. (TCON) and BioXcel Therapeutics Inc. (NASDAQ:BTAI) The NBO NewsTRACON Pharmaceuticals Inc. (NASDAQ:TCON) and BioXcel Therapeutics Inc. (NASDAQ:BTAI) compete against each other in the Biotechnology sector.